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Abstract
Background: Burkholderia cenocepacia is a member of the Burkholderia cepacia complex group of bacteria that cause
infections in individuals with cystic fibrosis. B. cenocepacia isolate J2315 has been genome sequenced and is
representative of a virulent, epidemic CF strain (ET12). Its genome encodes multiple antimicrobial resistance pathways
and it is not known which of these is important for intrinsic or spontaneous resistance. To map these pathways,
transcriptomic analysis was performed on: (i) strain J2315 exposed to sub-inhibitory concentrations of antibiotics and the
antibiotic potentiator chlorpromazine, and (ii) on spontaneous mutants derived from J2315 and with increased resistance
to the antibiotics amikacin, meropenem and trimethoprim-sulfamethoxazole. Two pan-resistant ET12 outbreak isolates
recovered two decades after J2315 were also compared to identify naturally evolved gene expression changes.
Results: Spontaneous resistance in B. cenocepacia involved more gene expression changes and different subsets of
genes than those provoked by exposure to sub inhibitory concentrations of each antibiotic. The phenotype and altered
gene expression in the resistant mutants was also stable irrespective of the presence of the priming antibiotic. Both
known and novel genes involved in efflux, antibiotic degradation/modification, membrane function, regulation and
unknown functions were mapped. A novel role for the phenylacetic acid (PA) degradation pathway genes was
identified in relation to spontaneous resistance to meropenem and glucose was found to repress their expression.
Subsequently, 20 mM glucose was found to produce greater that 2-fold reductions in the MIC of multiple antibiotics
against B. cenocepacia J2315. Mutation of an RND multidrug efflux pump locus (BCAM0925-27) and squalene-hopene
cyclase gene (BCAS0167), both upregulated after chlorpromazine exposure, confirmed their role in resistance. The
recently isolated outbreak isolates had altered the expression of multiple genes which mirrored changes seen in the
antibiotic resistant mutants, corroborating the strategy used to model resistance. Mutation of an ABC transporter gene
(BCAS0081) upregulated in both outbreak strains, confirmed its role in B. cenocepacia resistance.
Conclusions: Global mapping of the genetic pathways which mediate antibiotic resistance in B. cenocepacia has
revealed that they are multifactorial, identified potential therapeutic targets and also demonstrated that putative
catabolite repression of genes by glucose can improve antibiotic efficacy.
Background
Burkholderia cepacia complex (Bcc) bacteria are antibiotic
resistant opportunistic pathogens known for their ability
to infect individuals with cystic fibrosis (CF). The complex
currently consists of 17 formally named species, of which
B. multivorans and B. cenocepacia most often cause infec-
tion in CF [1]. The B. cenocepacia ET12 strain is one of
the most problematic Bcc strains infecting patients with
CF. It was most likely recognised as early as 1984 in the
pioneering studies of Isles et al. [2] that showed that
“P. cepacia“ could cause an invasive, frequently fatal infec-
tion that became known “cepacia syndrome.” Subsequent
s t u d i e sd e m o n s t r a t e dt h a tE T 1 2s t r a i n sc o u l dt r a n s m i t
between CF patients by social contact [3], had spread
intercontinentally across North America and Europe, and
could replace infection with other Bcc species (reviewed
[4]). Isolates of the ET12 strain can be identified using a
number of characteristics including presence of the cable
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marker, a RAPD 02 genotype fingerprint, a recA subgroup
III-A phylotype (reviewed [5]), and most recently as pos-
sessing the multilocus sequence type (MLST) ST-28 [6].
As a result of the devastating CF infections caused by the
B. cenocepacia ET12 strain, it has become one of the most
studied Bcc bacteria in terms of virulence [7] and antimi-
crobial resistance [8,9].
The B. cenocepacia ET12 isolate, J2315, was recovered
from an infected CF patient in Edinburgh, UK, in 1989 [3]
and has been subject to complete genome sequence analy-
sis [6]. This genomic resource enabled a B. cenocepacia
microarray to be designed that has greatly enhanced our
molecular understanding of this CF pathogen [10,11].
B. cenocepacia encodes multiple pathways that it uses to
resist killing by antimicrobial agents, including efflux
pumps [12], lipopolysaccharide, beta-lactamases and a tri-
methoprim resistant dihydrofolate reductase enzyme [6].
A problematic feature of chronic Bcc infection in CF is the
ability of the infecting strain to adapt to very high levels of
antibiotic resistance. The emergence of pan resistant Bcc
strains, which are either untreatable or require combina-
tions of multiple antibiotics to suppress exacerbations of
infection, is of great concern [8]. The molecular mechan-
isms behind the evolution of spontaneous antimicrobial
resistance in B. cenocepacia are not known and how the
multiple resistance pathways function on a global scale to
allow B. cenocepacia to survive antibiotic therapy is poorly
understood. Cationic drugs such as chlorpromazine and
theophylline have been shown to reduce the minimal inhi-
bition concentration (MIC) of certain antibiotics that are
otherwise ineffective against Bcc bacteria [13] and a more
complete understanding of how these non-antibiotic drugs
act may also provide novel therapies.
In this study, we employed a transcriptomic, microarray-
based strategy to investigate the following (Figure 1): (i)
how exposure to sub-inhibitory concentrations of three
antibiotics (amikacin, meropenem and trimethoprim-sulfa-
methoxazole) that are widely used to treat CF infections
[14] and sub-inhibitory exposure to the cationic drug
chlorpromazine affect gene expression in B. cenocepacia,
(ii) how B. cenocepacia alters gene expression after the
selection of spontaneous resistant mutants by the three lat-
ter antibiotics, and finally, (iii) how the antimicrobial resis-
tance characteristics and global gene expression of the
strain have naturally evolved during the 19 years it has cir-
culated within the CF community since the isolation of the
genome sequenced isolate, B. cenocepacia J2315 in 1989.
Results and discussion
Antibiotic susceptibility of B. cenocepacia J2315 and
derived mutants with spontaneous resistance
Using the clinically defined MIC breakpoints, wild type
B. cenocepacia J2315 was resistant to 15 of the 17
antibiotics tested; susceptibility to meropenem and cef-
tazidime was classified as intermediate (Table 1).
Synergy testing indicated no synergy in any of the com-
bination of two antibiotics tested against J2315. The
antibiotic potentiator chlorpromazine reduced the MIC
of amikacin (200 to 100 mg/L), tobramycin (150 to 50
mg/L) and azithromycin (50 to 15 mg/L) at a concentra-
tion of 0.2 mM; the same concentration of prochlorper-
azine produced slightly greater reductions in antibiotic
MIC (amikacin to 20, tobramycin to 20 and azithromy-
cin to 10 mg/L). These reductions were consistent with
previous data obtained for “B. cepacia“ strain ATCC
13945 [13] which is a B. cenocepacia IIIA strain, but not
from the ET12 lineage (see http://pubmlst.org/bcc. As
theophylline was not found to alter the susceptibility of
strain J2315, chlorpromazine in combination with ami-
kacin was selected as the optimal potentiator-antibiotic
combination to examine from the B. cenocepacia global
gene expression perspective because it had a good addi-
tive effect, did not present solubility problems in growth
medium as seen with prochlorperazine, and allowed
reproducible growth curves to be obtained for strain
J2315.
Spontaneous mutants with elevated resistance to ami-
kacin (J2315-A), meropenem (J2315-M) and trimetho-
prim-sulfamethoxazole (J2315-T) were generated by
plating on selective agar containing each respective anti-
biotic (see Methods). The mutants had MICs that were
increased over the wild type, 2.3-, 2.1- and 5-fold, for
each respective antibiotic (Table 1). The growth rate of
each mutant was unaltered in comparison to J2315 and
the resistant phenotype of each mutant was stable after
15 transfers on agar without antibiotics. The sponta-
neous mutants appeared at a frequency of 18.1 (± 7.9) ×
10
-7 for amikacin, 4.5 (± 0.5) × 10
-7 for meropenem,
and 14.4 (± 4.1) × 10
-8 for trimethoprim-sulfamethoxa-
zole; no difference in mutation frequency was observed
between J2315 cultures that were plated in log phase or
at the beginning of stationary phase. Mutant J2315-A
showed an increased resistance to all other aminoglyco-
sides tested, and interestingly also to the beta-lactams
meropenem, ceftazidime, cefotaxime and aztreonam
(Table 1). The meropenem-resistant mutant, J2315-M,
demonstrated elevated resistance to all beta-lactams
tested, as well as increases in tobramycin, chlorampheni-
col and tetracycline resistance. Mutant J2315-T was
more resistant to fluoroquinolones, chloramphenicol,
rifampicin and tetracycline (Table 1).
Antibiotic susceptibility and features of clonal outbreak
strains circulating 19 years after isolation of B.
cenocepacia J2315
Two isolates from two CF patients involved in a recent
ET12 outbreak [15], BCC1616 and BCC1617, were
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gene expression genotype. They represent the natural
evolution of this epidemic strain as an infectious agent
circulating in CF community since the recovery of J2315
in 1989. BCC1616 and BCC1617 were both found to be
clonally identical with J2315 (MLST ST-28). Each was
more resistant to aminoglycosides, macrolides, fluoro-
quinolones and tetracycline, than J2315 (Table 1);
BCC1616 was less susceptible to all beta-lactams tested.
This is in concordance with previous observations of
rapid evolution of elevated drug resistance within
sequential ET12 CF isolates, where isolates from epi-
sodes of clinical exacerbation were more resistant than
those recovered during stable clinical conditions [9].
The growth rate of BCC1616 and BCC1617 on Iso-sen-
sitest broth (doubling time = 3.0 and 2.4 hours, respec-
tively) was also slower than J2315 (doubling time = 1.8
hours). P. aeruginosa isolates recovered from CF infection
have reduced growth rates compared to those from other
sources [16] and a slower growth rate is also linked to
increased antibiotic resistance in bacterial pathogens [17].
Both of the recent ET12 clones were not motile in con-
trast to J2315 (Additional file 1, Figure S1). Loss of motility
has been observed among P. aeruginosa isolates recovered
from chronic CF infection [18]. Both J2315 and BCC1616
were auxotrophic for tyrosine and phenylalanine. Auxotro-
phy for amino acids has also been observed in CF isolates
of P. aeruginosa and B. cepacia [19] and is attributed to
the CF lung environment being rich in amino acids and
other nutrients, selecting for auxotrophic variants. J2315
and BCC1616 both formed a brown pigment at the begin-
ning of stationary phase on Iso-sensitest and on LB med-
ium. P. aeruginosa CF isolates often produce a brown,
melanin-like pigment, attributed to accumulation of
homogentisate in the growth medium [16]. The same phe-
nomenon has been observed for B. cenocepacia [20] with
B. cenocepacia
wild type
J2315 (1989)
Control = 
wild type
J2315 (1989)
AmikacinR
J2315-A
MeropenemR
J2315-M
Trimethoprim-
sulfamethoxazoleR
J2315-T
J2315-A + 
50 mg/L AMK
J2315-M +
2 mg/L 
meropenem
J2315-A + 
50 mg/L AMK
J2315-M +
8 mg/L 
meropenem
J2315-T +
10/50 mg/L 
TMP/SMX
J2315-M +
10/50 mg/L 
TMP/SMX
Control = 
wild type
J2315 (1989)
50 mg/L 
Amikacin
10/50 mg/L
Trimethoprim-
sulfamethoxazole
2 mg/L
Meropenem
0.05 mM
Chlorpromazine
0.05 mM
Chlorpromazine
+ 50 mg/L Amikacin
BCC1616 outbreak
strain patient A
(2008) Control = 
wild type
J2315 (1989)
BCC1617 outbreak 
strain patient B
(2008)
(iii) Evolution of antibiotic
resistance gene expression
in cystic fibrosis infection
(i) Gene expression during 
exposure to sub-MIC 
antibiotics
(ii) Gene expression after
selection of spontaneous
antibiotic resistance control
control
control
Figure 1 B. cenocepacia antimicrobial resistance traits examined by global gene expression. The flow chart shows the three major
questions addressed in regard to the antimicrobial resistance of B. cenocepacia (orange boxes). The microarray experiments performed to
investigate these questions are shown with the control condition given in the blue box and test condition indicated as follows: amikacin (green
boxes); meropenem (yellow boxes), trimethoprim-sulfamethoxazole (tan boxes); chlorpromazine (pink boxes); and the clonal outbreak strains
(turquoise). The exception to the latter designation was that each spontaneously resistance mutant was used as the control condition when they
were exposed to antibiotics.
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tance to oxidative stress. In contrast to J2315 and
BCC1616, strain BCC1617 was not auxotrophic and did
not produce a brown pigment, illustrating the known phe-
notypic variability of these bacteria [21].
B. cenocepacia global gene expression in the presence of
antibiotics
Transcriptomic analysis of strain J2315 was performed
on mid-log phase cultures exposed to amikacin, merope-
nem, trimethoprim-sulfamethoxazole, chlorpromazine
and a combination of amikacin and chlorpromazine
(Table 2). Expression analysis of the spontaneous
mutants was performed with and without each respec-
tive antibiotic on which the mutant had been selected;
antibiotic exposure was performed at the same antibiotic
concentration as used for J2315 and levels above this to
induce further responses in the spontaneous mutants
(Table 2). Validation of the microarray results was car-
ried out by qPCR analysis of 17 protein coding genes of
interest (Additional file 1, Table S1). In all cases the up-
or downregulation observed by qPCR correlated to the
microarray results corroborating previous studies using
the B. cenocepacia J2315 microarray [10,11,22].
Very few significant alterations in the expression of
features on the microarray were observed after exposure
of J2315 to amikacin (19 of 8740 probes; Table 2), while
exposure to meropenem and trimethoprim-sulfamethox-
azole resulted in approximately three times this number
of features altering in expression (Table 2). The pre-
sence of 0.05 mM chlorpromazine also altered a limited
number of features (18/8740), and this doubled with the
combination of chlorpromazine and amikacin (Table 2).
Overall, a greater number of genes were upregulated
than downregulated in each antimicrobial exposure con-
dition (Table 2). The number of differentially expressed
genes was significantly higher in all experiments where
the antibiotic resistant mutants were compared to J2315
(Table 2). The number of differentially expressed genes
was highest in the outbreak isolates BCC1616 and
BCC1617, with 255 and 198 differentially expressed
genes compared to J2315 (Table 2).
Gene expression in J2315 and J2315-A in response to
amikacin
The upregulation of tRNAs dominated the transcrip-
tomic response of J2315 to amikacin (15 of the 19 alter-
ing genes; Table 2); since this aminoglycoside targets
protein synthesis, the alteration of tRNA expression may
be correlated to the mode of action of amikacin but,
further research will be need to validate this assumption.
In terms of protein encoding genes only two were signifi-
cantly upregulated in the presence of 50 μg/ml amikacin:
BCAL1755, a protein with unknown function and the
adjacent gene, BCAL1756, a CDS with homology to
metal-dependent phosphohydrolases (Table 3). Both
were also upregulated in J2315-A (Table 3). The induc-
tion of BCAL1756 by the presence of amikacin was
Table 1 Antibiotic susceptibility (mg/L) of B. cenocepacia J2315, resistant mutants and outbreak isolates
Antibiotic clasBs Antibiotic name wild type
J2315
J2315-A
(AMK
r)
J2315-M
(MER
r)
J2315-T
(TMP
r)
BCC
1616
BCC
1617
Beta-lactams Meropenem 7 13 15 6 30 7
Imipenem 125 125 175 100 175 100
Ceftazidime 10 30 40 10 60 5
Cefotaxime 250 500 1200 250 >1500 15
Aztreonam 250 500 1500 200 >1500 40
Piperacillin 450 450 900 350 1500 40
Aminoglycosides Amikacin 200 450 200 200 450 900
Gentamicin 700 5000 450 400 10000 >10000
Tobramycin 150 500 300 125 1500 3000
Macrolides Azithromycin 50 40 40 30 200 >500
Erythromycin 150 150 200 150 500 800
Folate synthesis inhibitors Trimethoprim/Sulfamethoxazole 30/150 20/100 30/150 150/750 10/50 20/100
Fluoroquinolones Ciprofloxacin 7 7 8 30 >50 13
Levofloxacin 7 7 8 30 >50 13
Rifamycins Rifampicin 90 70 100 >200 60 80
Chloramphenicol Chloramphenicol 10 10 25 >400 15 15
Tetracyclines Tetracycline 60 70 180 120 160 >300
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BCAL1756 contains nucleotidyltransferase and phospho-
transferase motifs that could possibly confer similar
enzyme activities as those present in aminoglycoside-
modifying enzymes, and which have been implicated in
aminoglycoside resistance [23]. Introduction of the
BCAL1755/BCAL1756 region into B. vietnamiensis G4
(see Additional file 1 Table S2 for construct information)
which lacks homologous genes in its genome did not
result in transformants with an elevated resistance to
amikacin. Mobilization of the same construct into B. cen-
ocepacia K56-2 (Additional file 1 Table S2), a genetically
amenable B. cenocepacia strain that is frequently used as
a surrogate model for genetic manipulation due to diffi-
culties associated with J2315[ 7 ] ,d i dn o ti n c r e a s et h e
amikacin resistance of this strain by insertion of addi-
tional copies this locus. The function of these genes was
also tested by creating an isogenic knockout mutant in
B. cenocepacia strain, K56-2 (Additional file 1 Table S2).
In correlation with the gene transfer experiment deletion
of genes BCAL1755-6 in mutant K56-2ΔL1755-6 did not
result in increased susceptibility to aminoglycosides or
any other antimicrobial tested (Table 4).
The amikacin-resistant mutant J2315-A demonstrated
upregulation of different genes/gene clusters compared
to the wild type, regardless of the present or absence of
the antibiotic (Table 3). Most conspicuous was the
upregulation of a gene cluster on the large chromosome,
BCAL3148-3153. One of these genes, BCAL3152 encoded
a sigma factor (extracytoplasmatic function subfamily;
ECF) and an adjacent anti-sigma factor, BCAL3151.
The BCAL3152 sigma factor is highly conserved among
Burkholderia species [24]. ECF sigma factors are involved
in sensing and regulating the response to changes in the
environment, including maintaining cell envelope integrity
under stress [25]. The BCAL3148-3153 cluster was not
induced in the wild type by sub-inhibitory concentrations
of amikacin, but its constitutive upregulation in J2315-A
s u g g e s t e di tm a yp l a yam a j o rr o l ei nt h eg e n e r a ls t r e s s
response linked to the spontaneous adaptation to an ele-
vated state of antimicrobial resistance.
Another gene cluster found to be constitutively upregu-
lated in J2315-A was a putative acetyltransferase, BCAM
0829a, and a nearby ABC transporter gene, BCAM0831
(Table 3). Limited upregulation of BCAM0829a was
observed when J2315 was exposed to amikacin (Table 3)
but this was confirmed by qPCR (Additional file 1 Table
S1). Acetyltransferases are known mediators of aminoglyco-
side resistance [23] and ABC transporters often contribute
towards multi-drug resistance in E. coli [26], hence, both
genes, BCAM0829a and BCAM0831 have plausible roles in
functionally mediating resistance to amikacin. However,
transfer of the acetyltransferase BCAM0829a into B. vietna-
miensis G4 or B. cenocepacia K56-2 failed to alter their
Table 2 Number of B. cenocepacia genes with a >2-fold change in expression
B. cenocepacia strain and growth condition Number of genes significantly altered
in expression (>2 fold):
Exposure of J2315 to sub-MIC antimicrobials: Up-regulated Down-regulated Total
J2315 wt + 50 mg/L AMK 17 2 19
J2315 wt + 2 mg/L MEM 53 6 59
J2315 wt + 10/50 mg/L TMP/SMX 39 17 56
J2315 wt + 0.05 mM CPZ 13 5 18
J2315 wt + 0.05 mM CPZ + 50 mg/L AMK 19 16 35
J2315 resistant mutants:
J2315-A 26 28 54
a
J2315-A + 50 mg/L AMK 32 50 82
a
J2315-A + 250 mg/L AMK 37 38 75
a
J2315-M 39 59 98
a
J2315-M + 2 mg/L MEM 67 24 83
a
J2315-M + 8 mg/L MEM 39 74 113
a
J2315-T 41 39 80
a
J2315-T + 10/50 mg/L TMP/SMX 44 38 82
a
J2315-T + 60/300 mg/L TMP/SMX 52 53 105
a
ST28 outbreak isolates:
BCC1616 89 166 255
BCC1617 83 115 198
a The number of genes differentially expressed were significantly different (p < 0.001; one-way analysis of variance with square root transformation) in the
resistant mutants compared to the corresponding condition of J2315 exposed to each respective antibiotic.
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BExperimental condition from which the gene was
selected
Fold change observed under each microarray condition
Gene
name
Annotation
Exposure to amikacin J2315 wt +
50 mg/L AMK
J2315-A J2315-A +
50 mg/L AMK
J2315-A +
250 mg/L AMK
BCAL1233 Putative heat shock Hsp20-related protein - 1.95 3.47 4.92
BCAL1234 Putative heat shock protein - - 3.00 4.43
BCAL1755 Conserved hypothetical protein 2.44 - 4.74 3.47
BCAL1756 Putative metal dependent phosphohydrolase 1.78 - 2.95 3.14
BCAL1919 ClpB heat-shock protein - - - 3.20
BCAL2442 Chaperone protein HtpG - - - 2.39
BCAL3146 60 kDa chaperonin 1 - - - 2.47
BCAL3147 10 kDa chaperonin 1 - - - 2.96
BCAL3148 Polyketide cyclase/dehydrase and lipid transport
Family
- 2.14 3.27 1.95
BCAL3149 Outer membrane lipoprotein carrier protein
LolA
- 2.86 4.22 2.31
BCAL3150 Putative exported protein - 3.15 4.34 -
BCAL3151 putative transmembrane anti-sigma factor - 2.76 4.43 2.31
BCAL3152 putative RNA polymerase sigma factor, ECF
subfamily
- 2.94 4.77 3.40
BCAL3153 Putative lipoprotein - 3.47 5.82 4.45
BCAL3270 Putative DnaK chaperone protein - - - 2.76
BCAM0829a RimL, Acetyltransferases, including N-acetylases
of ribosomal proteins
- 2.51 2.46 2.14
BCAM0831 ABC transporter ATP-binding membrane protein - 1.91 2.43 3.01
BCAS0637 60 kDa chaperonin 3 - - - 6.62
BCAS0638 10 kDa chaperonin 3 - - - 7.88
Exposure to meropenem J2315 wt + 2
mg/L MER
J2315-M J2315-M + 2
mg/L MER
J2315-M + 8 mg/
L MER
BCAL0212 Putative phenylacetic acid degra-dation NADH
oxidoreductase PaaE
--- 3.32
BCAL0213 Phenylacetic acid degradation protein PaaD - - - 6.61
BCAL0214 Phenylacetic acid degradation protein PaaC - - - 3.14
BCAL0215 Phenylacetic acid degradation protein PaaB - 8.01 6.48 3.81
BCAL0216 Phenylacetic acid degradation protein PaaA - 14.83 10.03 6.79
BCAL0404 Phenylacetate-coenzyme A ligase - - - 2.58
BCAL0405 Phenylacetic acid degradation protein PaaI - - - 2.75
BCAL0406 Probable enoyl-CoA hydratase PaaG - 6.28 - 3.63
BCAL0407 Beta-ketoadipyl CoA thiolase - - - 4.48
BCAL0408 Putative phenylacetic acid degradation
oxidoreductase paaZ
- 9.93 7.93 5.75
BCAL0409 Putative phenylacetic acid degra-dation enoyl-
CoA hydratase PaaF
- 2.67 --
BCAL1804 Major Facilitator Superfamily protein - -3.45 -2.70 -1.85
BCAL1805 Putative sugar kinase - -4.76 -4.35 -2.22
BCAL1806 Conserved hypothetical protein - -14.29 -9.90 -5.26
BCAM1356 Putative gluconate 2-dehydrogenase subunit 3 - -25.64 -29.50 -12.85
BCAM1357 Gluconate 2-dehydrogenase flavoprotein
subunit
- -7.14 -7.30 -5.52
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BCAM1358 Gluconate 2-dehydrogenase cytochrome c
subunit
- -24.69 -25.38 -9.80
BCAM1710 Putative enoyl-CoA hydratase/isomerase - 3.23 - 4.32
BCAM1711 Phenylacetate-coenzyme A ligase paaK - 12.48 11.01 5.24
BCAM2165 Putative beta-lactamase, class A 53.35 - 60.30 60.62
BCAS0128 ABC transporter ATP-binding protein -2.27 -2.04 - -3.70
BCAS0129 Putative binding-protein-dependent transport
system component
-2.56 -2.13 - -4.98
BCAS0130 Putative ABC transporter substrate-binding
protein
-2.94 - -2.48 -6.25
BCAS0156 Beta-lactamase, class C 116.10 - 133.10 61.12
Exposure to trimethoprim sulfamethoxazole J2315 wt +
10/50 mg/L
TMP/SMX
J2315-T J2315-T + 10/
50 mg/L
TMP/SMX
J2315-T + 60/
300 mg/L TMP/
SMX
BCAL0145 Adenosylhomocysteinase 1.77 -- 2.26
BCAL0147 5,10-methylenetetrahydro-folate reductase 1.61 -- 2.07
BCAM0186 Lectin 2.90 -- -
BCAM1869 Conserved hypothetical protein - -3.68 -4.13 -2.09
BCAM1870 N-acylhomoserine lactone synthase CepI - -15.48 -14.95 -3.51
BCAM1871 Conserved hypothetical protein 2.03 -14.88 -12.90 -3.73
BCAM2549 Multidrug efflux system outer membrane
protein
- 138.20 111.80 35.80
BCAM2550 Multidrug efflux system transporter protein - 108.80 103.60 30.79
BCAM2551 Multidrug efflux system transport protein CeoA - 296.90 341.50 55.38
BCAM2552 Putative hydrolase - 187.40 167.50 45.93
BCAM2554 LysR family regulatory protein - 4.34 4.36 2.40
BCAS0292 Conserved hypothetical protein 3.41 -6.02 -4.03 -
BCAS0293 Nematocidal protein AidA 8.56 -6.02 -5.65 -2.67
BCAS0409 ZmpA 1.99 -- -
Exposure to chlorpromazine J2315 wt +
0.05 mM CPZ
J2315 wt + 0.05 mM CPZ +
50 mg/L AMK
BCAL1233 Putative heat shock Hsp20-related protein - 2.98
BCAL1234 Putative heat shock protein - 2.40
BCAL1755 Conserved hypothetical protein - 2.07
BCAL1756 Conserved hypothetical protein 2.04 1.82
BCAM0923 Putative lipoprotein 11.00 11.33
BCAM0924 Two-component regulatory system, response
regulator protein
4.85 4.63
BCAM0925 Multidrug efflux system outer membrane
protein
12.80 16.51
BCAM0926 Multidrug efflux system transporter protein 17.75 27.45
BCAM0927 Multidrug efflux system transport protein 13.75 22.43
BCAM2186 Putative macrolide-specific efflux system
transport protein
1.96 2.04
BCAM2187 Putative ThiJ/PfpI family protein 1.60 2.02
BCAS0167 Squalene-hopene cyclase 4.36 5.35
BCAS0168 TetR family regulatory protein 2.33 2.81
BCAS0638 10 kDa chaperonin 3 4.18
Sass et al. BMC Genomics 2011, 12:373
http://www.biomedcentral.com/1471-2164/12/373
Page 7 of 18susceptibility to amikacin, gentamicin and tobramycin (with
or without chloropromazine), and deletion of the associated
ABC transporter gene BCAM0831 in mutant K56-2ΔM
0831 also did not reveal an antimicrobial phenotype
(Table 4).
Gene expression in J2315 and J2315-M in response to
meropenem
The global gene expression response of B. cenocepacia to
meropenem was characterised by upregulation of predict-
able factors such as beta-lactamases and of novel enzymes
like those linked to the phenylacetic acid (PA) degradation
pathway (Table 3). BCAS0156, a class C beta-lactamase
encoded on the small chromosome was the most upregu-
lated gene seen when the wild type was exposed to mero-
penem; a class A beta-lactamase, BCAM2165, encoded on
the medium chromosome was also highly expressed
(Table 3). Interestingly, neither beta-lactamase was signifi-
cantly altered in expression in the meropenem resistant
mutant in the absence of the antibiotic (Table 3), indicat-
ing that these enzymes were not primarily involved in the
elevated resistance phenotype of J2315-M (Table 1).
Located 135 bp upsteam of the class A beta-lactamase
BCAM2165 was a LysR family regulator BCAM2166, with
90% homology to and in a location corresponding to that
of penR previously described in “P. cepacia” [27] (now
known to be a B. multivorans strain). This region is
conserved in all completed Burkholderia genomes and
Trépanier et al. [27] showed that penR controlled the tran-
scription of the class A beta-lactamase penA with a puta-
tive binding site mapped to a region 130 bp upstream of
the beta-lactamase, directly adjacent to the regulator
sequence. A motif search revealed the same binding site in
J2315, upstream of both BCAM2165 and BCAS0156, sug-
gesting that they may be co-regulated and possibly under
the control of the BCAM2166 regulator.
Although both beta-lactamases were upregulated in the
presence of meropenem, it was not known which, if any,
is active against the antibiotic. Carbapenem hydrolyzing
class A beta-lactamases have been reported for Klebsiella
pneumoniae [28]. A class A penB beta-lactamase has
been characterised in B. cenocepacia [29] that is active
against penicillin and cephalosporins, but has only a mar-
ginal ability to degrade meropenem and imipenem.
Table 4 B. cenocepacia K56-6 deletion mutants and their phenotype
Mutant
name
Gene(s)
deleted
Gene annotation Relevant experiment/microarray
observation
Phenotype
a
K56-
2ΔL1755-
6
BCAL1755
BCAL1756
Hypothetical
protein
Phosphohydrolase
Upregulated in the presence of amikacin, in
J2315-A and in BCC1617
None observed
K56-
2ΔM0831
BCAM0831 ABC transporter Upregulated in the presence of amikacin None observed
K56-
2ΔS0293-
2
BCAS0292
BCAS0293
Hypothetical
protein
Nematocidal
protein AidA
Upregulated in the presence of TMP/SMX None observed
K56-
2ΔM0924
BCAM0924 Response regulator
protein
Upregulated in the presence of
chlorpromazine
None observed
K56-
2ΔM0925-
7
BCAM0925
BCAM0296
BCAM0297
Multidrug efflux
system OMP
Multidrug efflux
system protein
Multidrug efflux
system protein
Upregulated in the presence of
chlorpromazine
Increased susceptibility for chlorhexidine (14 μg/ml, wt
22 μg/ml)
Increased susceptibility for azithromycin (100 μg/ml, wt
150 μg/ml)
Decreased growth rate in the presence of 1.0 mM
chlorpromazine (μ = 0.49, wt μ = 0.55)
K56-
2ΔM2186-
8
BCAM2186
BCAM2187
BCAM2188
Efflux system
transport protein
ABC-type efflux
carrier protein
Outer membrane
efflux protein
Upregulated in the presence of
chlorpromazine
None observed
K56-
2ΔS0167
BCAS0167 Squalene-hopene
cyclase
Upregulated in the presence of
chlorpromazine
Increased susceptibility for chlorhexidine (13 μg/ml, wt
22 μg/ml)
Decreased growth rate in the presence of 1.0 mM
chlorpromazine (μ = 0.62, wt μ = 0.80)
K56-
2ΔS0081
BCAS0081 ABC transporter Upregulated in outbreak strains BCC1616
and BCC1617
Increased susceptibility for chlorhexidine (14 μg/ml, wt
22 μg/ml)
Increased susceptibility for tetracycline (100 μg/ml, wt
150 μg/ml)
a The following antibiotics and antimicrobials were tested on all mutants, except K56-2ΔS0167: amikacin, tobramycin, meropenem, ceftazidime, trimethoprim,
azithromycin, erythromycin, levofloxacin, tetracycline, chloramphenicol, chlorhexidine
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imipenemase activity has also been reported [30]. To
clarify the involvement of BCAM2165 in meropenem
inactivation by B. cenocepacia, clavulanic acid was tested
as a class A-specific beta-lactamase-inhibitor, but it failed
to reduce the MIC for meropenem even at concentra-
tions as high as 64 mg/L (data not shown). The role of
the class C beta-lactamase, BCAS0156 was tested by
complementation into B. vietnamiensis G4 which lacks
this gene (see Additional file 1 Table S2 for construct).
The resulting transformant showed an increase in MIC
for cefotaxime (from 8 to 35 mg/L), ceftazidime (from
7 to 50 mg/L), imipenem (from 8 to 40 mg/L) and piper-
acillin (from 4 to 15 mg/L), but the MIC for meropenem
(0.35 mg/L) and aztreonam (6 mg/L) remained
u n c h a n g e df r o mt h a to fw i l dt y p eB. vietnamiensis G4.
When the same construct was mobilized into B. cenoce-
pacia K56-2, the MIC for cefotaxime (300 to 400 mg/L)
and ceftzidime (40 to 45 mg/L) increased, but the
remaining antibiotic MICs were unaltered. Addition of
chlorpromazine to the complemented strains did not
alter their antibiotic susceptibility further. A functional
role for BCAS0156 in mediating high level beta-lactam
resistance was therefore supported, but interestingly not
for meropenem as a specific substrate for this class C
beta-lactamase.
Three gene clusters annotated as phenylacetic acid
degradation enzymes [31,32] were upregulated in
mutant J2315-M regardless of the presence or absence
of the meropenem (Table 3). In B. cenocepacia,t h e s e
genes are organised as follows: two gene clusters on the
large chromosome (BCAL0212-0216, BCAL0404-0409)
and one gene cluster on the medium chromosome
(BCAM1710-1712). All three clusters appeared largely
co-regulated from the microarray data and a MEME
search revealed a common regulatory motif [33] for all
three locations, upstream of BCAL0216, BCAL0408 and
BCAM1712 respectively. A MAST analysis revealed the
same regulatory motif to be present upstream of the PA
degradation genes in all genome sequenced Burkhol-
deria species. Upregulation of BCAL0216, BCAL0408,
and BCAL1711/12 was confirmed by qPCR (Additional
file 1 Table S1).
Two sets of genes involved in glucose transport and
metabolism via the pentose phosphate pathway were sub-
stantially down regulated in the resistant mutant J2315-
M: BCAL1804-1806 and BCAM1356-1358 (Table 3).
Growth curve analysis showed that J2315-M grew at less
than half the growth rate on glucose than J2315. The PA
catabolic enzymes have been shown to be under glucose
catabolite repression in B. cenocepacia [33]. Our data
therefore suggested that for J2315-M to achieve the upre-
gulation of PA genes and increase its meropenem resis-
tance, it had to down regulate the glucose transport and
metabolism genes to lower the intracellular glucose con-
centration. The resulting slower growth rate of J2315-M
in presence of glucose may also be an advantageous phe-
notype for surviving antimicrobial exposure, analogous to
the alterations seen in small colony variants [34].
To elucidate if the PA catabolic enzymes aid resistance
to antibiotics, MIC values in the presence and absence of
glucose (20 mM) in LB medium were determined. The
presence of glucose resulted in reductions of ≥ 2-fold in
J2315’s MIC for meropenem (50 to 15 mg/L), ceftazidime
(275 to 160 mg/L), chloramphenicol (16 to 8 mg/L) and
tetracycline (50 to 10 mg/L); no change was observed for
amikacin, tobramycin, erythromycin, levofloxacin and tri-
methoprim-sulfamethoxazole. A panel of 17 closely related
B. cenocepacia were also tested and 7 out of 17 also
demonstrated a reduction in meropenem MIC in the pre-
sence of 20 mM glucose (data not shown). Analysis of PA
gene expression directly correlated to these phenotypic
observations, being considerably reduced in J2315 (48-fold
by qPCR for BCAL0216) in the presence of glucose.
Expression of this gene was unaltered by addition of glu-
cose for B. cenocepacia K56-2, which did not demonstrate
the same MIC reduction for meropenem.
The strain to strain variability of this putative catabolite
repression response suggest that the regulation of central
metabolism in B. cenocepacia is highly complex; given the
number of paralogous metabolic pathways present in
Burkholderia genomes [35] such plasticity is not surpris-
ing. qPCR showed that the expression of the beta-lacta-
mases (BCAM2165 and BCAS0156) was not affected by
the presence of glucose in J2315 indicating that these
degradative antibiotic resistance enzymes were not catabo-
lite repressed. The role of the PA degradation enzymes in
Burkholderia is not yet fully understood, but recently it
was shown that PA pathway is necessary for full patho-
genicity during Caenorhabditis elegans infection [36]. The
linkage of PA degradation to the phenomenon of sponta-
neous antibiotic resistance in B. cenocepacia adds further
complexity to the central role aromatic metabolism plays
in the biology of these microorganisms.
Gene expression in J2315 wt and J2315-T in response to
trimethoprim-sulfamethoxazole
The gene encoding a homologue of AidA (BCAS0293), a
quorum sensing regulated gene required for full virulence
of B. cenocepacia H111 during C. elegans infection [37]
was the most upregulated gene when wild type J2315 was
exposed to sub-inhibitory levels of TMP-SMX (Table 3).
Other quorum sensing regulated genes such as the zinc
metalloprotease [38], ZmpA (BCAS0409), and the lectin
encoding BCAM0186 [11] were also upregulated. Few
other significant alterations were made by J2315 in
response of sub-lethal amounts of TMP-SMX (Table 3).
Deletion of BCAS0293 together with the adjacent
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susceptibility to trimethoprim, sulfamethoxazole, or any
other antimicrobials (Table 4).
The TMP-SMX resistant mutant J2315-T also altered
the expression of a limited number of genes, however,
the most conspicuous change it made was a strong and
constitutive upregulation of an efflux pump of the RND
family, BCAM2549-2552 (Table 3). This is the J2315
homologue of the ceo multidrug efflux pump operon
described by Nair et al. [39] consisting of the three parts
of the efflux pump (BCAM2549-2551) and a hydrolase/
lipase (BCAM2552). The MIC data for J2315-T showed
increased resistance to trimethoprim, fluorquinolones,
chloramphenicol and tetracyclines (Table 1; all are
known substrates for this pump), a phenotype consistent
with the substrate spectrum of the ceo efflux pump
described by Nair et al. [39] and thus corroborating the
microarray expression data. Upstream and divergently
transcribed from the ceo efflux pump is a LysR family
regulatory protein, BCAM2554, that is a homologue of
the ceoR transcriptional activator [39]. This regulator was
constitutively upregulated in mutant J2315-T (Table 3).
Nair et al. [39] had also shown that the pump was upre-
gulated in the presence of salicylate. In contrast to their
findings made on B. cenocepacia strain PC121 [39],
where salicylate and chloramphenicol were found to
induce expression of the ceo efflux pump, we found that
both the efflux pump and ceoR in B. cenocepacia J2315
and K56-2 were not inducible by salicylate (as tested by
qPCR, data not shown) or sub-inhibitory levels of TMP-
SMX (Table 3).
Gene expression in J2315 wt in response to
chlorpromazine
Exposure of B. cenocepacia to this potentiator of amino-
glycoside activity resulted in significant upregulation of
two efflux gene clusters, BCAM0923-0927 and to a lesser
extent, BCAM2186-2188 (Table 3). No specific link to
amikacin-related gene expression, the antibiotic most
potentiated by chlorpromazine, was observed (Table 3).
The BCAM2186-2188 pump had homology to a macro-
lide-specific ABC-type efflux pump system in E. coli [26].
Transfer of the efflux pump genes to B. vietnamiensis G4
or B. cenocepacia K56-2 (Additional file 1 Table S2) did
not alter the antimicrobial susceptibility of these strains
(either with or without the addition of chlorpromazine).
Likewise creation of a B. cenocepacia deletion mutant
K56-2ΔM2186-8 did not produce an observable pheno-
type in relation to the antibiotics (with or without chlor-
promazine) examined in this study (Table 4).
In relation to the other chlorpromazine activated efflux
system, BCAM0926 and BCAM0927, were closely related
to MexD and MexC, respectively, components of the
MexCD-OprJ efflux pump in P. aeruginosa [40].
BCAM0925, an outer membrane protein, is most similar
to OprM, which is part of the MexAB-OprM efflux
pump in P. aeruginosa [40]. BCAM0924 is the response
regulator part of a two component regulatory system that
may control expression of the efflux pump; its role was
investigated by the construction of a deletion mutant
K56-2ΔM0924 (Table 4). The mutation did not alter its
chlorpromazine or antibiotic MIC (Table 4). The expres-
sion of the structural pump genes, BCAM0926-0927, was
also still induced by chlorpromazine in the deletion
mutant suggesting that BCAM0924 was not critical for
regulation of the adjacent efflux pump (data not shown).
To further investigate the role of the efflux pump
structural genes BCAM0925-0927, a K56-2 deletion
mutant spanning all 3 genes was constructed (Table 4).
The K56-2ΔM0925-7 mutant demonstrated increased
susceptibility to the disinfectant chlorhexidine and the
antibiotic azithromycin, but no alteration in susceptibil-
ity to other antibiotics. Growth curve analysis of the
K56-2ΔM0925-7 mutant revealed a 10% slower growth
rate in the presence of chlorpromazine compared to the
parent strain. qPCR analysis of the K56-2 parent strain
showed that chlorhexidine, as well as chlorpromazine
induced the efflux pump gene BCAM0927, 345-fold in
t h ep r e s e n c eo f5μg/ml chlorhexidine and 125-fold in
the presence of 0.05 mM chlorpromazine. Chlorhexi-
dine, like chlorpromazine is a cationic compound
known to interact with and damage cellular membranes
[41], hence it is logical that both compounds induce the
efflux pump and that the efflux mutant demonstrated
sensitivity to this disinfectant. Chlorhexidine is also
known to induce the Pseudomonas aeruginosa MexCD-
OprJ efflux pump [41]. Since the BCAM0925-0927
efflux operon shares considerable homology with latter
P. aeruginosa system, the mutant phenotype also sug-
gests that the pump may play a role in chlorhexidine
efflux in B. cenocepacia. Why deletion of the pump led
to an alteration in susceptibility to azithromycin is not
known.
Another gene cluster upregulated in the presence of
chlorpromazine was a squalene-hopene cyclase, BCAS0167,
and an adjacent, divergently transcribed response regulator,
BCAS0168 (Table 3). Squalene-hopene cyclase is involved
in the synthesis of hopanoids, the prokaryotic equivalent of
steroids [42] which may function to counter the effect of
membrane disrupting agents on bacterial cells. A deletion
mutant of BCAS0167, K56-2ΔS0167, demonstrated
reduced growth rate in the presence of chlorpromazine and
chlorhexidine, as well as an increased susceptibility to
chlorhexidine (Table 4). Since the squalene-hopene cyclase
gene and surrounding region is highly conserved in several
Bcc genomes (B. cenocepacia, B. multivorans, B. lata and B.
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intrinsic resistance of Burkholderia to membrane disrupt-
ing antimicrobial agents.
Gene expression in the pan-resistant CF outbreak isolates
BCC1616 and BCC1617
The most pronounced change in expression profiles of
both ET12 outbreak isolates was the downregulation of
genes involved in flagella production and in chemotaxis
(Table 5) compared to J2315. BCC1616 and BCC1617
also downregulated expression of their cable pilus genes
(Table 5). The lack of flagella and chemotaxis gene
expression correlated directly to the non-motile pheno-
type of the outbreak isolates, in contrast to J2315 which
was motile (Additional file 1, Figure S1). During rapid
growth in a sputum-based medium J2315 upregulates
genes involved in production of the flagellum [10]. This
may reflect a short term response of B. cenocepacia to
early growth during infection, where flagella and moti-
lity serve as important virulence factors [43]. Lack of
motility has been observed in P. aeruginosa CF isolates
from chronic infection [18] and as a global gene expres-
sion adaptation to growth in sputum [44]. The stable
non-motile phenotype and genotype of the recent ET12
clinical strains suggest that B. cenocepacia may in time
also adapt to the same phenotype associated with P. aer-
uginosa from chronic CF infection.
Both the outbreak isolates had upregulated genes
involved in transport and efflux, restriction modification,
and transposition as follows (Table 5). An ABC mem-
brane transport protein (BCAS0081; 41-fold) and adja-
cent hypothetical protein with possible hydrolytic activity
(BCAS0082; 35-fold) were highly expressed. The trans-
port protein BCAS0081 contains both an ATP binding
cassette and transmembrane components, and has
homology to the mdlB gene of E. coli which is implicated
in multidrug resistance [45]. Deletion of BCAS0081 in
mutant K56-2ΔS0081 resulted in increased susceptibility
to tetracycline and chlorhexidine, but did not alter the
MIC for the other antimicrobial agents tested (Table 4).
These data validate the microarray observed upregulation
of BCAS0081 and demonstrate it does play a role in the
antimicrobial resistance of B. cenocepacia.
Also highly upregulated in both strains were genes of a
type I restriction modification system (BCAL0414-0420;
Table 4). In J2315, the first gene in this operon is a pseu-
dogene mutated with an insertion sequence (IS) that may
prevent expression of the entire downstream gene clus-
ter. PCR amplification and sequence analysis of this
region revealed that BCC1616 and BCC1617 do not pos-
sess the same IS mutation, hence allowing overexpression
of the genes as detected by the microarray analysis.
Mutation of the putative DNA methylase, BCAL0417, in
this cluster results in the attenuation of B. cenocepacia
virulence in a rat lung model of chronic lung infection
(mutant 16_E1 [46]). The DNA modification conferred
b yt h eg e n ec l u s t e rm a ya l s op l a yar o l ei ns u r v i v i n gt h e
damage caused by hydroxyl radicals which are released
when bacteria are exposed to bactericidal antibiotics [47].
Since the type I restriction modification cluster is clearly
transcriptionally activated in the outbreak strains, it will
be interesting to follow up if their expression has pro-
vided them with a resistance and virulence advantage
compared to J2315 as an ancestral ET12 isolate.
Another response conserved between the two outbreak
isolates was the upregulation of transposase encoding
genes within ISBcen9 (multiple probes were on the
microarray; see BCAL0044 and BCAM2637, Table 5).
The IS profiles of B. cenocepacia isolates of the same
MLST strain type have been recently shown to vary
markedly and oxidative stress was linked to this IS move-
ment [48]. The upregulation of the ISBcen9 transposase
in these recent outbreak isolates may indicate that these
strains are hypermutable with regard to this IS. This may
allow very rapid phenotypic switches to occur within
individual bacteria in the infecting population and alter
their pathogenicity.
When examined individually, the two outbreak isolates
demonstrated several global gene expression characteris-
tics that had been observed in the antibiotic resistant
B. cenocepacia J2315 derivatives. BCC1616 upregulated
the PA degradation enzyme genes (Table 5), that were
also constitutively upregulated in J2315-M (Table 2).
These data re-enforce the hypothesis that the ability of
B. cenocepacia to switch metabolism to alternative path-
ways in terms of aromatic hydrocarbon degradation
plays a critical role in its spontaneous antibiotic resistance.
It had also upregulated the class A beta-lactamase
(BCAM2165) that was induced in J2315 and J2315-M
upon meropenem exposure (Table 3). Phenotypically,
BCC1616 possessed the same elevated resistance to beta-
lactam antibiotics that J2315-M had developed after mero-
penem selection (Table 1), and its meropenem MIC could
be reduced by growth in the presence glucose (data
not shown). Genes found upregulated in the amikacin-
resistant J2315-A derivative (BCAL3148-3152; Table 5)
were also constitutively over-expressed in BCC1616, again
correlated to high aminoglycoside resistance of this isolate
(Table 1).
Several differentially expressed genes were specific to
isolate BCC1617. Genes involved in the p-hydroxy-
benzoate degradation pathway were highly upregulated
(BCAL0057-0063, BCAM2568, and the IclR family posi-
tive regulator protein BCAM2569; Table 5). Since the
PA pathway genes were not significantly altered in
BCC1617, it would be interesting to follow up if the
p-hydroxybenzoate degradation pathway may provide an
alternative metabolic shift for B. cenocepacia to evolve
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compared to B. cenocepacia J2315
Functional class and gene name Annotation Fold change in expression
1)
BCC1616 BCC1617
Motility and chemotaxis
BCAL0113 B-type flagellar hook-associated protein 2 -18.80 -11.33
BCAL0114 flagellin (type II) -38.91 -24.51
BCAL0126 chemotaxis protein MotA -3.22 -2.41
BCAL0127 chemotaxis protein MotB -5.68 -
BCAL0128 chemotaxis two-component response regulator CheY -6.76 -2.95
BCAL0129 chemotaxis two-component sensor kinase CheA -6.80 -3.26
BCAL0130 chemotaxis protein CheW -3.11 -2.82
BCAL0521 flagellar FliJ protein -4.31 -3.28
BCAL0576 flagellar hook-associated protein 1 (HAP1) -11.57 -5.38
BCAL0577 flagellar hook-associated protein 3 (HAP3) -14.33 -6.21
BCAL0762 putative methyl-accepting chemotaxis protein -3.32 -2.99
BCAM1503 putative methyl-accepting chemotaxis protein -16.92 -9.90
BCAL1662 putative methyl-accepting chemotaxis protein -4.98 -2.57
BCAM1804 methyl-accepting chemotaxis protein -12.56 -6.71
BCAM2564 putative aerotaxis receptor -6.45 -3.52
Cable pilus biosynthesis
BCAM2758 two-component regulatory system, sensor kinase protein -2.19 -2.63
BCAM2759 putative minor pilin and initiator - -3.69
BCAM2760 putative outer membrane usher -2.15 -2.96
BCAM2761 giant cable pilus -2.97 -6.90
BCAM2762 giant cable pilus chaperone protein -4.44 -10.00
Transport, efflux and antimicrobial resistance
BCAL1674 multidrug efflux system AmrA protein - 2.49
BCAL1756 Putative metal dependent phosphohydrolase - 1.97
BCAM2165 putative beta-lactamase, class A 2.45 -
BCAS0081 ABC transporter ATP-binding membrane protein 35.39 33.37
BCAS0082 Hydrolase of the alpha/beta superfamily 41.13 30.37
Restriction modification
BCAL0414_J_1 type I modification component of restriction-modification system (pseudogene) 23.04 24.84
BCAL0418 type I restriction enzyme specificity protein 12.59 10.77
BCAL0420 type I restriction component of type I restriction-modification system 3.79 3.04
Transposition
BCAL0044 putative transposase 3.75 2.91
BCAM2637 putative transposase 7.42 3.04
Aromatic hydrocarbon catabolism
BCAL0212 putative phenylacetic acid degradation NADH oxidoreductase PaaE 2.29 -
BCAL0213 phenylacetic acid degradation protein PaaD 5.19 -
BCAL0215 phenylacetic acid degradation protein PaaB 3.31 -
BCAL0216 phenylacetic acid degradation protein PaaA 3.06 -
BCAL0405 phenylacetic acid degradation protein PaaI 2.49 -
BCAL0406 probable enoyl-CoA hydratase PaaG 2.54 -
BCAL0407 beta-ketoadipyl CoA thiolase 4.38 -
BCAM1711 phenylacetate-coenzyme A ligase paaK 3.44 -
BCAM0058 3-oxoadipate CoA-transferase subunit A - 61.45
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nant upregulated in BCC1617 was an efflux pump
(BCAL1674; Table 5) that is a homologue of the
AmrAB [49] and of BpeAB [50] systems encoded by B.
pseudomallei. Both the latter systems mediate resistance
to aminoglycosides and macrolides in B. pseudomallei
and it was notable that BCC1617 possessed very high
levels of resistance to tobramycin, azithromycin and ery-
thromycin (Table 1). An adjacent gene BCAL1672,
encoding a transcriptional regulator and inactive in
J2315 due to a frameshift mutation, does not have the
frameshift in BCC1617 as revealed by sequence analysis.
Hence, this could in turn allow the upregulation of the
efflux pump in the outbreak strain compared to J2315.
BCC1617 also over expressed the phosphohydrolase
BCAL1756 which was stably upregulated in the J2315-A
amikacin exposed mutant. Other factors possibly contri-
buting to the overall antibiotic resistance in BCC1617
compared to J2315 is the absence of a frameshift muta-
tion in gene BCAL3259, a transport protein annotated
as tetracycline resistance protein, and absence of an
insertion sequence in BCAM1251, annotated as multi-
drug resistance transporter. Both latter genes are pseu-
dogenes in J2315 [6] and also in BCC1616 (data not
shown). Although their expression did not change in
BCC1617, by just being functionally expressed they may
mediate increased resistance to antibiotics.
Conclusions
Our novel transcriptomic analysis of the response of B.
cenocepacia to antibiotic exposure has demonstrated that
it expresses a multitude of genes and different pathways to
achieve high levels of resistance. B. cenocepacia J2315 and
the clonally related strains we studied are phenotypically
and transcriptomically very versatile and can adapt quickly
to environmental conditions. A key finding was that once
certain antibiotic resistance phenotypes in B. cenocepacia
had been selected by a single antibiotic, the changes in the
transcriptome were not transient, and were stably main-
tained in the spontaneous antibiotic resistant mutants.
This finding suggests that mutations selected in the spon-
taneously resistant B. cenocepacia J2315 mutants are stably
inherited and do not revert at a high frequency. A change
in antibiotic therapy may therefore not reverse a pre-
viously acquired B. cenocepacia spontaneous antibiotic
resistance trait. Our molecular analysis corroborates the
results of antibiotic susceptibility testing that demonstrate
focussing on a single antibiotic or antibiotic class for
therapy has limited efficacy and that multiple antibiotic
combinations [14] offer the best means to combat the
spontaneous resistance of this pathogen. We have identi-
fied multiple novel molecular pathways B. cenocepacia uti-
lises to resist sub-MIC levels of antibiotic. However, for
many of the genes altering expression in relation to anti-
biotic exposure we could not prove a direct involvement
resistance, with only 3 of the 8 B. cenocepacia antibiotic
resistance gene deletion mutants demonstrating increased
antimicrobial susceptibility. For spontaneous resistance to
single antibiotics, B. cenocepacia expresses set of genes
which are distinct from those altered by transient sub-
MIC exposure, and which are stably altered in expression
irrespective of the presence of the priming antibiotic.
Table 5 Selected genes differentially expressed in the recent B. cenocepacia outbreak strains BCC1616 and BCC1617
compared to B. cenocepacia J2315 (Continued)
BCAM0059 3-oxoadipate CoA-transferase subunit B - 70.43
BCAM0060 3-carboxy-cis, cis-muconate cycloisomerase - 30.44
BCAM0061 putative 3-oxoadipate enol-lactonase I - 37.36
BCAM0062 4-carboxymuconolactone decarboxylase - 48.08
BCAM0063 putative 4-hydroxybenzoate transporter - 5.79
BCAM2568 putative beta-ketoadipyl CoA thiolase - 35.88
BCAM2569 IclR family regulatory protein - 13.08
Miscellaneous genes
BCAL0297 putative thiamine biosynthesis oxidoreductase 5.69 2.50
BCAL1104 thiamine biosynthesis protein 4.24 3.01
BCAL1756 Putative metal dependent phosphohydrolase - 1.97
BCAL3152 putative RNA polymerase sigma factor, ECF subfamily 5.26 -8.93
BCAL3153 putative lipoprotein 6.89 -13.04
BCAM0186 lectin 7.89 -
BCAS0125 conserved hypothetical protein 31.75 -
BCAS0126 MarR family regulatory protein/acetyltransferase 9.18 -
BCAS0292 conserved hypothetical protein 3.98 -
Sass et al. BMC Genomics 2011, 12:373
http://www.biomedcentral.com/1471-2164/12/373
Page 13 of 18These findings suggest that spontaneous antibiotic resis-
tance in B. cenocepacia selects multiple individual as well
as pleiotropic mutations, stably altering the expression of
many genetic pathways; uncovering the location of these
mutations by genome re-sequencing and polymorphism
analysis in future studies would shed light on why these
changes are stably inherited traits in B. cenocepacia.O f
the B. cenocepacia resistance mechanisms identified, those
such as the beta-lactamases, phosphohydrolases, novel
efflux pumps and phenylacetic acid pathways genes may
be targeted to improve the efficacy of current antibiotics.
We may also be able to harness the phenomenon of bac-
terial catabolite repression by glucose as a novel means to
improve the efficacy of aerosolised antibiotics against cer-
tain B. cenocepacia during CF infection.
Methods
Bacterial strains and growth
B. cenocepacia strains J2315, K56-2, BCC1616 and
BCC1617, B. vietnamiensis G4, Escherichia coli strains
and plasmids used in this study are shown in Additional
file 1, Table S2. Bacteria were grown on Iso-sensitest
agar/broth (Oxoid, Basingstoke, UK), Tryptic Soya agar/
broth (TSA/TSB; Oxoid, Basingstoke, UK) Luria Bertani
agar/broth (LBA/LB; Sigma-Aldrich, St. Louis, MO,
USA) or minimal medium (BSM [51]) as required.
Strains BCC1616 and BCC1617 were from an outbreak
of B. cenocepacia ET12 infection among CF patients that
occurred in 2008 [15] and were confirmed to be the same
sequence type as J2315 (ST-28 [6]) by sequence analysis
of the phaC, gyrB and trpB g e n e s[ 5 2 ] .T h ep r e s e n c eo r
absence of pseudogenes in BCC1616/1617 in comparison
to strain J2315 was also determined using PCR (primer
sequences are shown in Additional file 1, Table S3) and
sequencing. P. aeruginosa ATCC 27853 was used as an
antibiotic susceptible reference strain for antimicrobial
analysis. LB was supplemented with 20 mM glucose for
testing of catabolite repression and antibiotic susceptibil-
ity as described below. Bacterial stocks were maintained
at -80°C as suspensions of fresh plate growth in TSB con-
taining 8% dimethyl sulphoxide.
Microbial growth characteristics were determined using
a Bioscreen Automated Microbial Growth Analyzer
(Bioscreen C, Oy Growth Curves AB, Finland). Cells were
grown in honeycomb microtiter plates at 37°C with 200 μl
medium per well and an inoculum of 5 × 10
5 colony form-
ing units (CFU) per ml. Optical density was measured
every 5 min at 420-580 nm wideband after shaking for 5
seconds. Swimming motility [18] was determined in Iso-
sensitest medium with 0.3% agar. Triplicate cultures were
grown in each experiment and data from two biological
replicates analyzed.
Spontaneous mutants with elevated antibiotic resistance
were selected by plating strain J2315 onto Iso-sensitest
agar containing antibiotic concentrations that were
approximately double the MIC as follows: Amikacin
(AMK) 300 mg/L; meropenem (MEM) 15 mg/L; and tri-
methoprim (TMP) in combination with sulfamethoxazole
(SMX), 100 and 500 mg/L, respectively. The mutation
frequency was calculated by dividing the total number
spontaneous mutants by the total number of viable cells
plated onto each selective agar. Single colonies were puri-
fied by plating, and five subsequent growth passages on
agar containing the elevated antibiotic concentrations
were performed prior to storage of the spontaneous anti-
biotic resistant mutant.
Determination of miminum inhibitory concentrations
MICs of antibiotics were determined using a broth micro-
dilution technique in 96-well microtiter plates according
to the British Society for Antimicrobial Chemotherapy
(BSAC) guidelines [53]. Antibiotics were obtained from
Sigma (amikacin, clavulanic acid potassium salt, erythro-
mycin, gentamycin, levofloxacin, piperacillin sodium,
rifampicin, sulfamethoxazole, tetracycline, tobramycin, tri-
methoprim), Fluka (azithromycin, ciprofloxacin) or MP
Biomedicals (chloramphenicol). Meropenem was obtained
from Chemos and ceftazidime from Sandoz. Clarofan
from Aventis was used as a source of cefotaxime, Primaxin
IV from Merck as a source of imipenem, and Azactam
from Bristol-Myers Squibb for aztreonam. The non-anti-
biotic cationic drugs theophylline, chlorpromazine and
perchlorperazine were all obtained from Sigma. For the
spontaneous J2315 mutants, the antibiotic on which they
were selected was not included in the MIC assays.
Microtiter plates containing 200 μl of Iso-sensitest broth
per well were inoculated with 5 × 10
5 CFU/ml of bacteria
obtained by dilution of a fresh overnight culture. After
incubation (routinely 24 h, but up to 40 h for slow grow-
ing isolates) at 37°C (with rotary shaking at 200 rpm)
growth was monitored spectrophotometrically (630 nm)
using a microtiter plate reader (MRX-TC Revelation,
Dynex Technologies, Worthing, UK). Wells with an O.D.
>0.1 were scored as positive for growth. The BSAC guide-
lines were followed for determining breakpoint sensitiv-
ities [54]. To evaluate additive or synergistic antibiotic
effects of two compounds in combination, a checkerboard
microdilution assay with 1.5-fold dilution steps was used.
The mean fractional inhibitory concentraction (FIC) index
was calculated according to standard procedures. Synergy
was defined as an FIC index of ≤ 0.5, additivity or indiffer-
ence was defined as an FIC index of >0.5 to 4 [55].
Microarray analysis
Bacteria were cultivated for the microarray experiments
in 25 ml Iso-sensitest medium held in 250 ml flasks;
each was inoculated with 5 × 10
8 CFU and incubated at
37°C on a rotary shaker (150 rpm). Antibiotics and
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tions at the time of inoculation (the concentrations are
given in Table 2 and Figure 1). The concentrations were
chosen because they resulted in a 20% reduction of
growth rate, this ensuring the bacteria were affected by
the antibiotics but not in a lethal way. In the case of
spontaneous mutants, experiments were performed at
two different antibiotic concentrations: the same con-
centrations as used for the wild type (which did not
alter the growth rate of the mutants significantly), and a
higher concentration, again chosen to reduce the growth
rate of each mutant by 20%. Growth was monitored
spectrophotometrically and the bacteria harvested at an
O.D. of 0.5 (approximately 5 × 10
8 CFU/ml). Cultures
were swiftly aliquoted into microcentrifuge tubes and
snap-cooled in liquid nitrogen before centrifuging at
20.000 × g at 4°C for 1 min. Pellets were immediately
frozen at -80°C and RNA was extracted within one week
o fh a r v e s tu s i n gt h eR i b o P u r eB a c t e r i aK i t( A m b i o n /
Applied Biosystems) including the optional DNase I
treatment of the kit. LiCl precipitation (Ambion/Applied
Biosystems) was used to concentrate the RNA and its
quality was assessed with a Bioanalyzer using the RNA
6000 Nano kit (Agilent).
RNA was indirectly labelled with the CyScribe Post-
Labelling Kit (GE Healthcare), with the first strand cDNA
generated using random nonamers and incorporating
amino allyl-dUTPs, which were then chemically labelled in
a second step to minimise any dye bias. 10 μgo ft o t a l
RNA were used per labelling reaction and Spike-In con-
trols (Agilent) were added to the labelling mix. B. cenoce-
pacia genomic DNA was extracted as described [56] and
labelled with the CyScribe Array CGH Genomic DNA
Labeling System (GE Healthcare) at 1 μg per labelling
reaction. A reference design was used for the microarray
experiments with Cy3 labelled reference RNA or genomic
DNA run as the control channel for all experiments. All
experiments were performed with three biological repli-
cates, and compared to three biological replicates of a
J2315 control grown on Iso-sensitest medium without any
antibiotics.
A custom microarray for B. cenocepacia J2315 was
used, [10] however, the design was updated with each
probes printed four times in a randomised distribution
using the Agilent SurePrint 4 × 44K microarray platform
(design AMADID#017397; ArrayExpress http://www.ebi.
ac.uk/arrayexpress accession number A-MEXP-1613).
Microarrays were hybridized according to the Two-Col-
our Microarray Based Gene Expression Analysis protocol
(Agilent), except that it was adjusted for the use of cDNA
by omitting the fragmentation step. Labelled experimen-
tal cDNA was used at 825 ng per microarray and labelled
control genomic DNA was used at 200 ng per microar-
ray. Hybridization, washing and scanning was performed
as described in the Two-colour Microarray protocol and
the data analysed using GeneSpring GX version 7.3.1.
8740 probes (7251 coding sequences [CDS] and 1489
intergenic [IG]) specific to J2315 were evaluated as follows:
(i) unreliable features were filtered out (features had to
have a p-value ≤ 0.05 in at least half of the samples to be
used for analysis); (ii) a filter on 1.5-fold change in expres-
sion in the test condition compared to the control condi-
tion (wild type without antibiotics) was applied, and (iii) a
one-way ANOVA was carried out on the resulting gene
lists, using a Welch t-test with 5% false discovery rate (and
without multiple testing correction). An initial cut-off of
2-fold change was used for global analysis of differential
gene expression. To verify co-regulation of adjacently
encoded genes, those within clusters, or those with known
roles in antibiotic resistance, a more relaxed cut-off of 1.5-
fold change was used and reported if found to be statisti-
cally significant. The microarray raw data is accessible in
ArrayExpress (accession numbers E-MEXP-2708, -2738
and -2747) and the complete gene expression dataset
(including the statistical confidence data) is available as a
supplementary data spreadsheet (Additional file 2).
qPCR for validation of microarray results
qPCR primers and annealing temperatures are listed in
Additional file 1, Table S3. The correct size of amplifica-
tion product and absence of unspecific product was con-
firmed by PCR on genomic DNA and subsequent agarose
gel electrophoresis. RNA was extracted with the RiboPure
Bacteria Kit (Ambion/Applied Biosystems) from newly
generated biological replicates as follows: (i) one set
mimicking the same culture conditions and concentrations
of antibiotics used for microarray experiments; (ii) two sets
of biological replicates where the culture conditions were
modified and J2315 was grown on Iso-sensitest medium to
O.D.600 0.5 without drugs, before adding higher but still
sub-inhibitory concentrations of drugs (AMK 250 mg/L,
MEM 20 mg/L, TMP-SMX 50 and 250 mg/L, chlorpro-
mazine 0.25 mM). This reduced the doubling time by 10
to 20%, and then the control and test cultures were har-
vested after further growth to O.D.600 1.0. Extracted RNA
was diluted to 150 ng/μl and treated for a second time
with DNase (RQ1, Promega). cDNA was generated with
the ImProm-II Reverse Transcription System (Promega)
using 200 ng RNA per reaction. Real-time qPCR was per-
formed as described in Drevinek et al. [10] using 250 ng
cDNA per reaction; non-amplification, non-template, and
no reverse transcriptase controls were included in all
assays. Multiple reference genes were evaluated as controls
for qPCR (data not shown) and BCAM0918, encoding
RpoD, selected as the most stably expressed control gene
as it showed minimal changes in expression across all con-
ditions used in this study. Fold changes were calculated
according to the delta delta CT method. qPCR was also
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ferent strains (J2315, K56-2 and J2315-M; see below)
under the following conditions: LB medium with and
without glucose (20 mM), and with and without salicylate
(10 mM). Growth, RNA extraction and qPCR was per-
formed exactly as described above.
Genetic manipulation
B. vietnamiensis G4 was used as an antibiotic susceptible
complementation host for genes or gene clusters impli-
cated in antibiotic resistance and with no close homolo-
gues in this strain. Genes were cloned into the arabinose
inducible pMLBAD vector and introduced into B. vietna-
miensis G4 by triparental mating [57]. The correct insert
identity was confirmed by sequencing. Primer sequences
for construction of the vectors are listed in Additional file
1, Table S3. Selection after triparental mating was per-
formed on tryptone soya agar containing 75 mg/L tri-
methoprim and 400 U/ml polymyxin. MIC tests were
performed on two transformants of each gene and gene
cluster tested and compared to B. vietnamensis G4 trans-
formed with pMLBAD. The test medium was supplemen-
ted with arabinose at 0.5% final concentration, no
trimethoprim selection was applied during the MIC tests.
B. cenocepacia K56-2 was used for mutagenesis experi-
ments and unmarked deletions were constructed using the
yeast homing endonuclease I-SceI, as described by Flanna-
gan et al. [58]. Transformation was performed by electro-
poration. Primer sequences for construction of pGPI
derivatives are listed in Additional file 1, Table S3. All
mutations were confirmed by PCR and subsequent pheno-
typic testing was carried out on two independently isolated
mutants.
Bioinformatic analysis
Putative promoters and regulator binding sites were pre-
dicted by analysing the upstream region of upregulated
genes with the motif discovery tool MEME [59]. The bind-
ing sites predicted by MEME were used for a search
against genomes of other Burkholderia species using the
MAST tool [60]. Signal peptides were predicted using Sig-
nalP 3.0 [61] and subcellular location of proteins was pre-
dicted with PSORT-B [62]. Homologues for genes across
the genus Burkholderia were searched for by BLASTp [63]
or the Burkholderia Genome Database [64].
Additional material
Additional file 1: Supplementary tables and figures. A single
document containing the following supplementary material: (i) Table S1:
Fold changes in B. cenocepacia gene expression determined by qPCR; (ii)
Table S2: Strains and plasmids used in this study; (iii) Table S3: PCR
primers used in this study; and (iv) Figure S1. Swimming motility of B.
cenocepacia J2315 and the outbreak isolates.
Additional file 2: Summary of significant changes in B. cenocepacia
J2315 gene expression observed for all the conditions tested.A n
Excel spreadsheet of all genes significantly altering their expression
under the conditions examined is provided. Columns are provided for
the systematic gene identifier (Gene ID) and its functional annotation in
the B. cenocepacia genome [6], the fold gene expression change under
the conditions examined (see Figure 1), and the statistical confidence p-
value associated with each gene expression change.
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